Combination therapy with ruxolitinib plus low-dose cytarabine or mercaptopurine in patients with blast-phase myelofibrosis
Patients with myelofibrosis in blast-phase commonly have a median overall survival of only 3–6 months. Given the older median age of onset and heavy pretreatment, intensive chemotherapy often is not appropriate and has low efficacy with high toxicity. Ruxolitinib (a JAK1/2 inhibitor) has provided si...
| Principais autores: | , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Russian |
| Publicado em: |
ABV-press
2016-08-01
|
| coleção: | Онкогематология |
| Assuntos: | |
| Acesso em linha: | https://oncohematology.abvpress.ru/ongm/article/view/195 |